The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
How Is The Market Size Of The Non-Proliferative Diabetic Retinopathy Market Expected To Change Between 2026 And 2030?
The non-proliferative diabetic retinopathy market has shown robust expansion in recent years. Its value is expected to increase from $2.83 billion in 2025 to $3.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The past growth in this market can be linked to several factors, including the significant incidence of diabetes, a lack of comprehensive understanding of retinal complications, the prevalent use of traditional laser treatments, the limited acceptance of intravitreal injections, and an inadequate screening infrastructure.
The market for non-proliferative diabetic retinopathy is projected to experience substantial expansion in the coming years, with expectations to reach $3.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.8%. Key factors contributing to this anticipated growth include the increasing prevalence of diabetic retinopathy, the growing uptake of anti-VEGF and steroid treatments, the proliferation of ophthalmology clinics and specialized facilities, advancements in retinal imaging technologies, and enhanced patient education and early detection initiatives. Significant trends expected during this period involve the greater use of anti-VEGF therapy for NPDR, an increase in intraocular steroid injections, the broader application of sophisticated laser surgery methods, the wider performance of vitrectomy procedures, and the ongoing incorporation of AI-driven retinal imaging and diagnostic tools.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15620&type=smp
Which Economic Or Industry Drivers Are Impacting The Non-Proliferative Diabetic Retinopathy Market?
The expanding occurrence of diabetes is anticipated to foster the development of the non-proliferative diabetic retinopathy market in the future. Diabetes is defined as a persistent metabolic ailment marked by elevated blood sugar levels, resulting from insufficient insulin production by the pancreas or cellular resistance to insulin’s effects. Contributing factors to diabetes include inactive lifestyles, poor eating habits, and genetic susceptibility. Diabetes leads to non-proliferative diabetic retinopathy by harming the retina’s blood vessels, mainly due to prolonged high glucose concentrations in the bloodstream, which can cause impaired vision and potential blindness. As an illustration, in June 2024, data from the National Health Service, a UK government body, revealed that in 2023, the NHS detected more than half a million (549,000) new individuals in England facing a risk of type 2 diabetes, elevating the total number of individuals with non-diabetic hyperglycemia, or pre-diabetes, recorded by a GP to 3,615,330. This marks a notable surge from 3,065,825 in 2022, indicating an increase of nearly 20%. Consequently, the rising incidence of diabetes is propelling the expansion of the non-proliferative diabetic retinopathy market.
How Is The Non-Proliferative Diabetic Retinopathy Market Structured Across Different Segments?
The non-proliferative diabetic retinopathy market covered in this report is segmented –
1) By Treatment Type: Anti-Vascular Endothelial Growth Factor (VEGF) Therapy, Intraocular Steroid Injection, Laser Surgery, Vitrectomy
2) By Disease Severity Level: Mild Non-Proliferative Diabetic Retinopathy, Moderate Non-Proliferative Diabetic Retinopathy, Severe Non-Proliferative Diabetic Retinopathy
3) By End-User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Other End-Users
Subsegments:
1) By Anti-Vascular Endothelial Growth Factor (VEGF) Therapy: Bevacizumab (Avastin), Ranibizumab (Lucentis), Aflibercept (Eylea), Pegaptanib (Macugen)
2) By Intraocular Steroid Injection: Triamcinolone Acetonide, Dexamethasone Implant (Ozurdex), Fluocinolone Acetonide Implant (Iluvien)
3) By Laser Surgery: Focal Laser Photocoagulation, Panretinal Photocoagulation
4) By Vitrectomy: Pars Plana Vitrectomy (PPV), Membrane Peeling Vitrectomy, Phaco-Vitrectomy (Combined Cataract And Vitrectomy Surgery)
Which Trends Are Shaping The Future Of The Non-Proliferative Diabetic Retinopathy Market?
Leading companies in the non-proliferative diabetic retinopathy (NPDR) market are prioritizing the development of advanced clinical solutions, such as Phase 3 registrational trial enrollment, to bolster therapeutic validation, generate robust evidence, and facilitate regulatory approval for emerging NPDR treatments. This Phase 3 registrational trial enrollment involves the formal initiation and randomization of patients into a pivotal late-stage clinical trial, specifically designed to yield comprehensive efficacy and safety data essential for market authorization of a therapeutic intervention. For instance, in November 2025, Ocular Therapeutix, a US-based biopharmaceutical company focused on retinal diseases, announced the first patient randomization in the HELIOS-3 Phase 3 registrational program, which is evaluating AXPAXLI (OTX-TKI) for NPDR. AXPAXLI is an investigational bioresorbable intravitreal hydrogel containing axitinib, a tyrosine kinase inhibitor with anti-angiogenic activity, engineered to provide sustained therapy with fewer injections. The HELIOS-3 trial, alongside HELIOS-2, adopts an innovative ordinal ≥2-step Diabetic Retinopathy Severity Score (DRSS) improvement as its primary endpoint and includes patients with non-center-involved diabetic macular edema (non-CI-DME), thereby positioning AXPAXLI as a potentially transformative option for durable and effective NPDR management.
Which Major Players Dominate The Non-Proliferative Diabetic Retinopathy Market?
Major companies operating in the non-proliferative diabetic retinopathy market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Abbott Laboratories, Novartis AG, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Genentech Inc., Carl Zeiss Meditec AG, ZEISS Group, Santen Pharmaceutical Co. Ltd., Santen Inc., Topcon Corporation, Lumenis Ltd., Alimera Science, Ocular Therapeutix Inc., Acucela Inc., Kowa Company Ltd.
Read the full non-proliferative diabetic retinopathy market report here:
What Are The Top-Performing Regions Within The Non-Proliferative Diabetic Retinopathy Market?
North America was the largest region in the non-proliferative diabetic retinopathy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-proliferative diabetic retinopathy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Non-Proliferative Diabetic Retinopathy Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15620&type=smp
Browse Through More Reports Similar to the Global Non-Proliferative Diabetic Retinopathy Market 2026, By The Business Research Company
Bladder Cancer Drugs Global Market Report
https://www.thebusinessresearchcompany.com/report/bladder-cancer-drugs-global-market-report
Adrenocortical Carcinoma Global Market Report
https://www.thebusinessresearchcompany.com/report/adrenocortical-carcinoma-global-market-report
Urothelial Carcinoma Treatment Global Market Report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model